<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742663</url>
  </required_header>
  <id_info>
    <org_study_id>DCSG 1213</org_study_id>
    <nct_id>NCT01742663</nct_id>
  </id_info>
  <brief_title>A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis</brief_title>
  <official_title>A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) to Solaraze® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the relative efficacy and safety of the test&#xD;
      formulation diclofenac sodium gel 3% (Taro Pharmaceuticals Inc.) to the marketed formulation&#xD;
      Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms) in the treatment of actinic keratosis.&#xD;
&#xD;
      Both the test and reference formulations will also be compared to a placebo formulation to&#xD;
      test for superiority.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence</measure>
    <time_frame>Study day 90 (30 days after completion of 60 days of treatment)</time_frame>
    <description>Bioequivalence will be determined by evaluating the proportion of patients in the test and reference groups with 100% clearance of all AK lesions in the treatment area.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Superiority to placebo</measure>
    <time_frame>Study day 90 (30 days after completion of 60 days of treatment)</time_frame>
    <description>The superiority of the test and reference gels against the placebo will be tested by the proportion of patients showing 100% clearance of actinic keratosis lesions at Day 90 (30 days after completion of 60 days of treatment)using the modified intent to treat population and last observation carried forward.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">435</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Diclofenac Sodium Gel 3%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solaraze® (diclofenac sodium) Gel 3%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Topical Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Topical Gel (Taro Pharmaceuticals Inc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac Sodium Gel 3%</intervention_name>
    <description>Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.</description>
    <arm_group_label>Diclofenac Sodium Gel 3%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solaraze® (diclofenac sodium) Gel 3%</intervention_name>
    <description>Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)applied twice daily for 60 days.</description>
    <arm_group_label>Solaraze® (diclofenac sodium) Gel 3%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Topical Gel</intervention_name>
    <description>Vehicle Topical Gel (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.</description>
    <arm_group_label>Vehicle Topical Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent form.&#xD;
&#xD;
          -  Immunocompetent male or non-pregnant, non-lactating female at least 18 years of age.&#xD;
&#xD;
          -  Diagnosis of AK with at least 5 and no more than 10 clinically typical, visable,&#xD;
             discrete, nonhyperkeratotic, nonhypertrophic AK lesions each at least 4 mm in diameter&#xD;
             on the face and/or bald scalp contained within a 25 cm2 treatment area.&#xD;
&#xD;
          -  Women either must be 1 year post-menopausal, surgically sterile, or if they are of&#xD;
             child-bearing potential they must have been using systemic birth control, IUD or&#xD;
             Norplant for at least 28 days prior to treatment start, or used barrier methods&#xD;
             consistently at least 14 days before study gel administration, had a normal menstrual&#xD;
             cycle for the month prior to the start of treatment, have a negative urine pregnancy&#xD;
             test result upon entry into the study and agree to use a medically accepted form of&#xD;
             birth control throughout the study period.&#xD;
&#xD;
          -  Free from any systemic or dermatologic disorder that, in the opinion of the&#xD;
             investigator, will interfere with the study results or increase the risks of AEs.&#xD;
&#xD;
          -  Any skin type or race, providing the skin pigmentation will allow discernment of&#xD;
             erythema.&#xD;
&#xD;
          -  Willingness and capability to cooperate to the extent and degree required by the&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active gastrointestinal ulceration or bleeding.&#xD;
&#xD;
          -  Current or history of severe renal or hepatic impairment.&#xD;
&#xD;
          -  Presence of atopic dermatitis, basal cell carcinoma, squamous cell carcinoma, eczema,&#xD;
             psoriasis, rosacea, sunburn or other possible confounding skin conditions on the face&#xD;
             or bald scalp.&#xD;
&#xD;
          -  Use within six months prior to randomization of oral isotretinoin.&#xD;
&#xD;
          -  Use within six months prior to baseline on the face or bald scalp of chemical peel,&#xD;
             dermabrasion, laser abrasion, PUVA therapy or UVB therapy.&#xD;
&#xD;
          -  Use within one month prior to baseline on the face or bald scalp of cryodestruction or&#xD;
             chemodestruction, curettage, photodynamic therapy, surgical excision, topical&#xD;
             5-fluorouracil, topical corticosteroids, topical diclofenac, topical Imiquimod,&#xD;
             topical retinoids or other treatments for actinic keratosis including glycolic acids&#xD;
             or over-the-counter products containing retinol, alpha or beta hydroxy acids.&#xD;
&#xD;
          -  Use within one month prior to baseline of immunomodulators or immunosuppressive&#xD;
             therapies, interferon, systemic corticosteroids or cytotoxic drugs.&#xD;
&#xD;
          -  Known allergies to diclofenac sodium, benzyl alcohol, polyethylene glycol monomethyl&#xD;
             ether 359, hyaluronate sodium or any excipients in the test or reference gels.&#xD;
&#xD;
          -  Receiving 5-Fluorouracil or other systemic cancer chemotherapy within 6 months prior&#xD;
             to study entry.&#xD;
&#xD;
          -  Any condition, medical, psychological or social, that, in the investigator's opinion,&#xD;
             would interfere with participation in the study.&#xD;
&#xD;
          -  Women who are pregnant or planning pregnancy or lactating during the study.&#xD;
&#xD;
          -  Participation in any investigational drug study within 30 days of enrollment or&#xD;
             previous participation in this study.&#xD;
&#xD;
          -  Employees or family members of employees of the research center or investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>December 3, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>January 19, 2014</last_update_submitted>
  <last_update_submitted_qc>January 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diclofenac Sodium Gel 3%</keyword>
  <keyword>Solaraze® (diclofenac sodium) Gel 3%</keyword>
  <keyword>Actinic Keratosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

